What MRC-Holland does

MRC Holland BV is a Netherlands-based biotechnology company founded in 1985 and headquartered in Amsterdam that develops, manufactures, and commercializes molecular diagnostic assays and supporting software for the detection of DNA copy number variants (CNVs) and methylation patterns associated with hereditary disorders and tumors. The company's proprietary MLPA (Multiplex Ligation-dependent Probe Amplification) technique is positioned as the gold standard for CNV detection in clinical genetic testing and research, and its digitalMLPA platform extends MLPA into next-generation sequencing workflows, enabling targeted analysis of up to roughly 1,200 DNA sequences in a single multiplexed reaction (e.g., NXtec D007 ALL with 951 probes, NXtec D024 KaryoProfiler with 1,587 probes). The product portfolio spans consumable probemixes and reagent kits (sold in 25-, 50-, and 100-reaction formats), barcode plates, the IVD-registered Coffalyser.Net analysis software, the research-use-only Coffalyser digitalMLPA software, and the MLPA Sample Anonymiser support tool, all manufactured under ISO 13485:2016 and increasingly certified under EU IVDR (2017/746). MRC Holland serves clinical genetic testing laboratories and academic/clinical research customers worldwide through direct website orders and a network of country-specific sales partners and distributors, generating revenue on a pay-as-you-go unit-pricing model per reaction kit. Marketing and customer engagement are conducted through a global website with country selectors, email newsletters, free virtual workshops and on-demand webinars, conference exhibitions (e.g., AMP), and an extensive support help centre, with the company remaining privately held and founder/CEO Jan Schouten-led with no disclosed external funding rounds, acquisitions, or parent-company relationships.

Name

MRC-Holland

Legal name

MRC Holland BV

Website

https://mrcholland.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

11–50 employees

Short description

MRC Holland develops and sells MLPA and digitalMLPA molecular diagnostic assays, reagent kits, and free Coffalyser analysis software for DNA copy number and methylation detection, serving clinical genetic testing laboratories and academic/clinical research customers worldwide.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostics reagents
• Copy number variation detection
• Genetic testing assays
• MLPA probemixes
• DigitalMLPA kits

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Reagent Sales: MRC Holland generates revenue through the sale of MLPA and digitalMLPA reagents, including probemixes, reagent kits, and barcode plates. Products are sold directly and through sales partners with pricing based on reaction count (25, 50, or 100 reactions).

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

MRC Holland develops, manufactures, and commercializes molecular diagnostic reagents and assay kits based on its proprietary MLPA and digitalMLPA technologies for the detection of DNA copy number variants and methylation patterns associated with hereditary disorders and tumors. The company sells probemixes, reagent kits, and barcode plates to clinical genetic testing laboratories and research facilities worldwide, and provides free Coffalyser analysis software as part of the workflow. Products are used in oncology (e.g., acute lymphoblastic leukemia, multiple myeloma), constitutional genetic disorder diagnostics, and karyotyping/genome-wide CNV characterization.

Product overview

MRC Holland develops molecular diagnostic technologies for DNA copy number and methylation pattern detection. Their core product lines include MLPA (Multiplex Ligation-dependent Probe Amplification) as the gold standard technique and digitalMLPA, which merges MLPA with next-generation sequencing for enhanced resolution. The product portfolio includes Coffalyser.Net (IVD-registered MLPA analysis software) and Coffalyser digitalMLPA (RUO analysis software), plus digitalMLPA assay panels such as NXtec D007 Acute Lymphoblastic Leukemia, NXtec D024 KaryoProfiler, and NXtec D006 Multiple Myeloma, along with supporting reagents, reagents kits, barcode plates, and the MLPA Sample Anonymiser Support Tool. Products are certified under ISO 13485 and comply with IVDR for in vitro diagnostic use.

Differentiator

Problem solved

Functional benefit

Brands

• SALSA: Underlying technology brand for MLPA products (SALSA MLPA, SALSA digitalMLPA)
• Coffalyser.Net
• Coffalyser digitalMLPA
• NXtec
• MLPA

Products and services

• NXtec D007 Acute Lymphoblastic Leukemia digitalMLPA assay detecting copy number variations in 73 genes and eight chromosomal regions associated with acute lymphoblastic leukemia (ALL). Contains 951 target probes including 524 probes for ALL-related genes and 250 karyotyping probes, used for risk stratification and detection of IKZF1 deletions, MTAP/CDKN2A/B co-deletions, and IKZF1plus profiles. For research use only (RUO).
• NXtec D024 KaryoProfiler digitalMLPA assay for detection of gross copy number changes encompassing all chromosomes at approximately 2-4 Mb resolution. Contains 1,587 probes including 1,180 probes for genome-wide CN characterization, used for chromosomal abnormality detection, ESC/iPSC characterization, genomic drift monitoring, and low-level mosaicism detection. For research use only (RUO).
• NXtec D006 Multiple Myeloma digitalMLPA assay detecting copy number alterations of genes and chromosomal regions involved in multiple myeloma. Contains 644 probes including 189 probes for 33 genes and 4 chromosomal regions, plus BRAF p.V600E mutation detection. For research use only (RUO).
• NXtec D008 DMD digitalMLPA assay designed for reliable detection of copy number variants in the DMD gene, launched as the first dedicated neuromuscular assay in the digitalMLPA catalogue.
• MLPA and digitalMLPA Reagents and Reagent Kits Reagent kits and probemix consumables used to perform MLPA and digitalMLPA reactions, sold in 100, 500, and 2,000 reaction kit configurations (DRK01-IL, DRK05-IL, DRK20-IL), along with barcode plates (BP01-IL, BP02-IL). Priced per unit and supplied to clinical and research laboratories worldwide.
• Coffalyser.Net Software Free, user-friendly MLPA analysis software with advanced quality control features for complete analysis of MLPA data. Registered for IVD use in Europe and Israel, with continuous updates and sheet library downloads.
• Coffalyser digitalMLPA Software Free digitalMLPA analysis software providing complete analysis of digitalMLPA data, including FASTQ file loading, automatic read recognition, advanced quality scores, and PDF report generation. For research use only (RUO).
• MLPA Sample Anonymiser Support Tool Free support utility that removes personal information from sample names and filenames in FSA files from ABI capillary electrophoresis devices before sharing with MRC Holland for troubleshooting purposes. Requires Microsoft .NET Framework v4.5.

Quantifiable outcome

• Clinically relevant alterations detected in 86% of adult ALL patients in study by Chiara Salvesi et al.
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• MailCampminorOthersMailCamp provides email distribution services for MRC Holland newsletters. MRC Holland uses MailCamp's services to send newsletters to subscribed customers.
• Schuttelaar & PartnersminorImplementation/ SI/ Consulting PartnerSchuttelaar & Partners handles technical maintenance of MRC Holland's main website (www.mrcholland.com) and may access data stored by the website including customer account details for technical troubleshooting and development purposes.
• Coriell InstitutecoreOthersCoriell Institute provides positive control samples for validation of MRC Holland products. Recommended positive samples from Coriell biorepository can be used with various MLPA and digitalMLPA probemixes.
• Thermo Fisher Scientific / Applied BiosystemscoreTechnology or IntegrationMRC Holland products are designed to work with capillary electrophoresis devices produced by Thermo Fisher Scientific/Applied Biosystems. FSA files from these devices are used for MLPA data analysis with Coffalyser.Net.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Strengths3 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mrcholland
• Facebookfacebook.com/100338261383169

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MRC-Holland